{"id":49,"date":"2021-03-21T17:25:00","date_gmt":"2021-03-21T16:25:00","guid":{"rendered":"http:\/\/crmw.fr\/?page_id=49"},"modified":"2023-02-21T11:55:31","modified_gmt":"2023-02-21T10:55:31","slug":"liens-vers-essais-clinique","status":"publish","type":"page","link":"https:\/\/crmw.fr\/?page_id=49","title":{"rendered":"Liens vers essais Clinique"},"content":{"rendered":"\n<div class=\"wp-block-file\"><a href=\"https:\/\/crmw.fr\/wp-content\/uploads\/2023\/02\/guide_patient_-_essai_clinique_RechercheMW_lien-vers-EC.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Guide Patient : Participer \u00e0 un essai clinique <\/a><\/div>\n\n\n\n<p><strong>Protocole 071102<\/strong> : Etude de phase 3, prospective, multicentrique, en ouvert, \u00e9valuant l&#8217;efficacit\u00e9, la s\u00e9curit\u00e9 et la tol\u00e9rance du vonicog alfa (Veyvondi\u00ae) , en association ou non avec l&#8217;Advate\u00ae, dans le traitement et la pr\u00e9vention des \u00e9pisodes de saignement et l&#8217;efficacit\u00e9 et la s\u00e9curit\u00e9 du vonicog alfa (Veyvondi\u00ae) dans les chirurgies programm\u00e9es, et le profil pharmacocin\u00e9tique du vonicog alfa (Veyvondi\u00ae), dans une population d&#8217;enfants atteints d&#8217;une maladie de Willebrand s\u00e9v\u00e8re<br> <a rel=\"noreferrer noopener\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932618?term=Von+Willebrand+Disease&amp;cond=Willebrand+disease&amp;draw=3&amp;rank=17\" target=\"_blank\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932618<\/a><\/p>\n\n\n\n<p><strong>Protocole SHP677-304<\/strong> : Etude de phase 3B, en ouvert, multicentrique \u00e9valuant la s\u00e9curit\u00e9 et l&#8217;efficacit\u00e9 du rVWF (Veyvondi\u00ae) dans une population adulte et p\u00e9diatrique de sujets atteints d&#8217;une forme s\u00e9v\u00e8re de maladie de Willebrand<br><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03879135?term=shp677&amp;cond=Willebrand+disease&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03879135<\/a><\/p>\n\n\n\n<p><strong>Protocole TAK-577-4005<\/strong> : Etude non interventionnelle d&#8217;estimation des risques d&#8217;apparition de certains \u00e9v\u00e8nements ind\u00e9sirables dans une population de patients atteints d&#8217;une maladie de Willebrand et trait\u00e9 par Vonicog alfa (Veyvondi\u00ae) <br><a rel=\"noreferrer noopener\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265078?term=tak+577&amp;cond=Willebrand+disease&amp;draw=2&amp;rank=3\" target=\"_blank\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265078<\/a><\/p>\n\n\n\n<p><strong>Protocole PKM16978<\/strong> : Etude de phase 1, en ouvert, d&#8217;\u00e9valuation de la pharmacocin\u00e9tique et la s\u00e9curit\u00e9, tol\u00e9rance d&#8217;une injection unique de rFVIIIc-XTEN (BIVV001) dans une population adulte de sujets atteints d&#8217;une maladie de Willebrand de type 2N ou 3<br><a rel=\"noreferrer noopener\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04770935?term=pkm16978&amp;cond=Willebrand+disease&amp;draw=2&amp;rank=1\" data-type=\"URL\" data-id=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04770935?term=pkm16978&amp;cond=Willebrand+disease&amp;draw=2&amp;rank=1\" target=\"_blank\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04770935<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Protocole 071102 : Etude de phase 3, prospective, multicentrique, en ouvert, \u00e9valuant l&#8217;efficacit\u00e9, la s\u00e9curit\u00e9 et la tol\u00e9rance du vonicog<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":89,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"colormag_page_container_layout":"default_layout","colormag_page_sidebar_layout":"default_layout","footnotes":""},"class_list":["post-49","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49"}],"version-history":[{"count":6,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/49\/revisions"}],"predecessor-version":[{"id":1175,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/49\/revisions\/1175"}],"up":[{"embeddable":true,"href":"https:\/\/crmw.fr\/index.php?rest_route=\/wp\/v2\/pages\/89"}],"wp:attachment":[{"href":"https:\/\/crmw.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}